Rapid-onset clozapine-induced hyperglycaemia: pathways of glycaemic dysregulation
Authors:
- 13 September 2021
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 14 (9) , e243938
Abstract
Clozapine is an atypical antipsychotic used in refractory schizophrenia, also efficient in alleviating dyskinesia in Parkinson’s disease. Despite its potency, this drug is associated with severe metabolic side effects, including increased risk for diabetes. We report the case of a 45-year-old overweight woman with Parkinson’s disease who presented with rapid-onset hyperglycaemia within 2 months after starting clozapine for refractory dyskinaesia. She had a history of gestational diabetes. At presentation, her blood glucose level was 505 mg/dL and glycated haemoglobin 12.4%, with no catabolic symptoms. Clozapine was suspended and metformin was started, but adequate glycaemic control was achieved only with insulin therapy, along with exenatide and empagliflozin afterwards. We assume that clozapine acted as a trigger for rapid deterioration of glycaemic control through direct pathophysiological mechanisms, rather than an indirect slowly evolving weight gain-related metabolic syndrome pathway. Clinicians should be aware of this complication, enabling timely diagnosis and proper treatment.Keywords
This publication has 15 references indexed in Scilit:
- Worldwide Differences in Regulations of Clozapine UseCNS Drugs, 2016
- Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetesJournal of Psychopharmacology, 2016
- Clozapine directly increases insulin and glucagon secretion from islets: Implications for impairment of glucose toleranceSchizophrenia Research, 2014
- Termination of Clozapine Treatment Due to Medical ReasonsThe Journal of Clinical Psychiatry, 2013
- Clozapine-Induced Mitochondria Alterations and Inflammation in Brain and Insulin-Responsive CellsPLOS ONE, 2013
- Which comes first: atypical antipsychotic treatment or cardiometabolic risk?Acta Psychiatrica Scandinavica, 2009
- Diabetic Ketoacidosis among Patients Receiving Clozapine: A Case Series and Review of Socio-Demographic Risk FactorsAnnals of Clinical Psychiatry, 2007
- Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion From Perifused Rat IsletsDiabetes, 2005
- Diabetes mellitus among parkinsonian patients treated chronically with clozapineParkinsonism & Related Disorders, 2004
- Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic StudyAmerican Journal of Psychiatry, 2000